LR
Therapeutic Areas
Newron Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Xadago (safinamide) | Parkinson's disease | Approved |
| Evenamide (NW-3509) | Schizophrenia (treatment-resistant) | Phase III |
| Sarizotan | Rett Syndrome | Phase III |
| Newron 2024 | Undisclosed rare CNS disease | Preclinical |
Leadership Team at Newron Pharmaceuticals
SW
Stefan Weber
Chief Executive Officer
RA
Ravi Anand
Chief Medical Officer
RG
Roberto Galli
Chief Financial Officer